Cadila Healthcare rises 4% on launch of pressurized Metered Dose Inhaler

Forglyn pMDI is priced at Rs 495 per pack and has been developed in-house using Zydus' innovations in formulation technology

Shares of Cadila Healthcare rose 4 per cent to hit a 52-week high of Rs 428 on the BSE on Thursday after the company launched India’s first pressurized Metered Dose Inhaler (pMDI) for patients suffering from chronic obstructive pulmonary disease. The pharmaceutical company's stock surpassed its previous high of Rs 423.50, touched on October 6, 2020.

Zydus Cadila announced that it is launching Forglyn pMDI, India’s first pressurized Metered Dose Inhaler (pMDI) with a combination of Long Acting Muscarinic Antagonist (LAMA) and Long Acting Beta Agonist (LABA) for patients suffering from Chronic Obstructive Pulmonary Disease (COPD) in India.